Diet/Nutrition Therapy |
|
|
Clinical Trial: Reduction of Triglycerides in Women on HRT
This study is currently recruiting patients.
Purpose
To test the effect of lifestyle intervention on subclinical cardiovascular disease measures in women taking HRT.
| Condition | Treatment or Intervention |
|---|---|
| Cardiovascular Diseases Atherosclerosis Postmenopause Heart Diseases | Behavior: diet, fat-restricted Behavior: exercise Drug: hormone replacement therapy Drug: estrogen replacement therapy |
MedlinePlus related topics: Heart Diseases; Heart Diseases--Prevention; Vascular Diseases
Study Type: Interventional
Study Design: Prevention, Randomized
Study start: September 2001; Expected completion: August 2006
BACKGROUND: Cardiovascular disease is a common cause of morbidity and mortality in older women. Better methods of prevention via health promotion are needed. Estrogen hormone replacement therapy (HRT) may beneficially affect women's cardiovascular health, based on evidence from observational studies, but recent trial evidence suggests HRT may actually lead to increased risk of cardiovascular disease in new users. Understanding this untoward effect of HRTand how to prevent it is a significant aim.
DESIGN NARRATIVE: Randomized trial of 500 women on HRT for at least two years, aged 52-60 years, and three or more years postmenopausal to test whether reduction in waist circumference, triglycerides, dense low density lipoprotein cholesterol (LDLc), number of LDL particles, C-reactive protein, plasminogen activator inhibitor-I ( PAI-I) by aggressive diet exercise, versus a health education control will decrease progression or result in regression of measures of subclinical vascular disease. The intervention is designed to reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight. The primary endpoint will be a 20 percent or at least a 20 mg decrease in triglyceride levels, a 5 cm decrease in waist circumference, and a 10 percent decrease in LDLc. This will result in changes in subclinical measurements including carotid ultrasound, electron beam computer tomography of the coronary and aorta, pulse wave velocity, endothelial function, and tonometry of the radial artery. Nuclear magnetic resonance spectroscopy of lipoproteins, inflammatory markers, and estrogen metabolites will also be evaluated.
Eligibility
Ages Eligible for Study: 52 Years - 60 Years, Genders Eligible for Study: Female
Criteria
Location and Contact Information
Pennsylvania
University of Pittsburgh, Pittsburgh, Pennsylvania, 15261, United States; Recruiting
Lewis H. Kuller, Study Chair
Lewis Kuller, University of Pittsburgh
More Information
Record last reviewed: December 2004
Last Updated: December 13, 2004
Record first received: September 7, 2001
ClinicalTrials.gov Identifier: NCT00023543
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -

